Therapeutic Asset Ratings
128 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
FLUOROURACILUM
Colon Cancer
Akeso
P4
BB
(70)
Calcium folinate pentahydrate
Colon Cancer
Akeso
P3
BB
(69)
Eloxatin
Colon Cancer
Sun Yat-sen University
P3
BB
(69)
Irinotecan
Colon Cancer
SCRI Development Innovations, LLC
P3
BB
(68)
MACROGOLS
Colon Cancer
University Medical Center Ho Chi Minh City (UMC)
P4
BB
(66)
PANITUMUMAB
Colon Cancer
IFOM ETS - The AIRC Institute of Molecular Oncology
P3
B
(63)
Cetuximab
Colon Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
P3
B
(62)
DEXAMETHASONE
Colon Cancer
Institute of Oncology Ljubljana
P4
B
(61)
LIDOCAINE
Colon Cancer
Institute of Oncology Ljubljana
P4
B
(61)
NEPENTHE
Colon Cancer
Tel Aviv University
P4
B
(61)
Cyclophosphamide
Colon Cancer
Essen Biotech
P2
B
(61)
Capecitabine
Colon Cancer
Sun Yat-sen University
P3
B
(60)
Epirubicin
Colon Cancer
Sun Yat-sen University
P3
B
(60)
Nivolumab
Colon Cancer
IFOM ETS - The AIRC Institute of Molecular Oncology
P3
B
(60)
Iodixanol
Colon Cancer
Brian Henick, MD
P2
B
(59)
MITOMYCIN C
Colon Cancer
City of Hope Medical Center
P4
B
(58)
Palbociclib
Colon Cancer
Lebanese University
P2
B
(58)
Pembrolizumab
Colon Cancer
Ismail Gögenur
P2
B
(58)
Atezolizumab
Colon Cancer
Baylor College of Medicine
P3
B
(57)
Dfn-15
Colon Cancer
University of Copenhagen
P3
B
(57)
Docetaxel
Colon Cancer
Sun Yat-sen University
P3
B
(57)
Acetylsalicylic Acid
Colon Cancer
M.D. Anderson Cancer Center
P3
B
(56)
Icosapent Ethyl
Colon Cancer
Massachusetts General Hospital
P3
B
(56)
Iparomlimab
Colon Cancer
Fujian Medical University
P3
B
(56)
Ipilimumab
Colon Cancer
IFOM ETS - The AIRC Institute of Molecular Oncology
P3
B
(56)
Showing 1 to 25 of 128 assets
Previous
Page 1 of 6
Next